A Look At Taysha Gene Therapies (TSHA) Valuation After FDA Alignment On TSHA-102 BLA Pathway
Simply Wall St
Last updated: May 11, 2026
Taysha Gene Therapies has confirmed its alignment with the FDA regarding the Biologics License Application (BLA) pathway for its gene therapy candidate, TSHA-102. This alignment includes crucial aspects of the pivotal trial design and the potential for a six-month interim analysis.
- The company has engaged in constructive discussions with the FDA concerning TSHA-102, a gene therapy aimed at treating previously untreated adult patients with giant axonal neuropathy (GAN).
- The FDA has agreed with Taysha's proposed pivotal trial design, a critical step toward potential regulatory approval.
- Furthermore, the FDA has indicated a willingness to consider a six-month interim analysis of the pivotal trial data.
- This interim analysis could potentially expedite the review process, allowing for an earlier assessment of TSHA-102's efficacy and safety.
- Taysha plans to provide further updates on the BLA submission timeline and trial progress in the coming months.
- The company is focused on advancing TSHA-102 through clinical development, with the goal of bringing a novel treatment option to patients with GAN.
- This FDA alignment represents a significant milestone for Taysha Gene Therapies and its development program for TSHA-102.
